Global News

Phase Forward Revenue, Profits Jump

Wednesday, July 25, 2007

Waltham, Mass.-based Phase Forward, a provider of electronic data capture (EDC), drug safety and data management solutions for clinical trials, reported second quarter revenues rose 28% to $31.5 million and profits doubled.

[Read More]

Type II Diabetes Drug Fails Primary Endpoint

Tuesday, July 24, 2007

Metabasis and Daiichi Sankyo issued negative results from a phase IIb trial of CS-917 for the treatment of type II diabetes. This multi-center, double-blind, placebo-controlled trial enrolled 392 subjects who were divided into four treatment arms to receive CS-917 at 50 mg BID or 100 mg BID, metformin at 850 mg BID or placebo, for three months. 

[Read More]

Fraudulent Study Broker Cherie Thibodeau Continues to Bilk Sites

Friday, July 20, 2007

As a public service to sites, CROs and biopharmaceutical companies, CenterWatch is posting a long excerpt of this week’s CWWeekly article about fraudulent study broker, Cherie Thibodeau.

If you have been defrauded of funds by Cherie Thibodeau, please contact CenterWatch at editorial@centerwatch.com.

[Read More]

Recent Industry Personnel News

Wednesday, July 18, 2007

  • London-based CRO Premier Research Group hired David Fitts, MPH, Ph.D as executive director, biostatistics. Fitts comes to Premier from EMD Pharmaceutical, part of German-based Merck KGaA, where he was vice president of the clinical R&D unit’s global biostatistics and data services group. Fitts will now be responsible for all of Premier biostatistics operations in the U.S.

[Read More]